Insights Cloud fosters healthy relationships between sponsors and CROs through greater transparency
PHILADELPHIA, PA – ERT, a leading eClinical solutions provider, including high-quality patient data collection and analysis, today announced enhancements to its Insights Cloud trial oversight solution that enable trial sponsors and clinical research organizations (CROs) to collaborate by sharing electronic monitoring visit reports and comprehensive issue management, tracking, and reporting. Insights Cloud brings simplicity to complex relationships by providing the transparency, accountability and flexibility that sponsors and CROs require to meet their shared goals. In addition to integrating data from all trial sources to deliver performance analytics, the solution is now using these same concepts to drive monitoring workflows and leverage data captured in trip reports as new electronic data assets. Protocol deviations and violations, site issues, and action items are electronically captured and integrated into Insights Cloud, providing a new layer of transparency and enabling sponsors and CROs to comply with emerging ICH E6 (R2) standards for adopting a more comprehensive approach to quality risk-based monitoring. “Sponsors and CROs are seeking new ways to simplify their relationships and to proactively mitigate risk in order to gain drug development efficiencies,” said Amy Furlong, Executive Vice President of eClinical Insights at ERT. “Insights Cloud’s enhanced trial oversight solution creates transparency among both parties, promoting collaboration and accountability to reduce issue resolution cycle times so they can move forward quickly, with confidence.” ERT is hosting a webinar on September 28 to demonstrate how sponsors and CROs can leverage the enhanced solution to drive efficiencies in clinical development. Registration details are available
here
. For additional information on Insights Cloud, visit
http://www.ert.com/insights-cloud
.
About ERT
ERT is a leading provider of high-quality patient data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services and clinical consulting that increase the accuracy and reliability of patient data and improve the efficiency of the clinical development process. ERT delivers widely deployed solutions in centralized Cardiac Safety, Respiratory, and electronic Clinical Outcome Assessments (eCOA) – which includes patient-, clinician-, observer- and performance-reported outcomes – and cloud-based analytics and performance metrics. By efficiently integrating these solutions through a system built upon a scientific and regulatory foundation, ERT collects, analyzes and delivers safety and efficacy data critical to the approval, labeling and reimbursement of pharmaceutical products. For more information see
www.ert.com
. Join ERT on
,
,
YouTube
and
.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.